SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production

AMSTERDAM, February 2 - SynCo Bio Partners B.V. today announced that it has signed two
commercial manufacturing agreements with an undisclosed US biopharmaceutical
company. Under the contract, SynCo will provide both process validation and
GMP commercial manufacturing services to support the commercial launch of two
separate biopharmaceutical products onto the US market.

SynCo has commenced with preparations for the manufacture of
conformance lots in advance of its client's BLA filings, expected in late
2010, in anticipation of commercial manufacturing commencing in 2011.

The products are both recombinant proteins, to be produced in
E. coli. These products will be manufactured in SynCo's large-scale GMP
facility and take the tally of marketed products manufactured at its
Amsterdam facilities to six, since SynCo's inception in 2000. SynCo has
previously supported process development efforts for both products; an
excellent example of how SynCo supports its clients' biopharmaceutical
development programs from early stage to commercial supply.

Pierre Warffemius, CEO of SynCo Bio Partners said, "This news
is a further example of how SynCo can offer a viable long-term manufacturing
choice to its clients. SynCo has grown steadily over the last ten years in a
very competitive market. The foundation of this growth has been our ability
to form strong and mutually beneficial relationships with our clients. As a
consequence, SynCo is one of few biopharmaceutical CMOs in the world with a
recognized track record in both clinical and commercial manufacturing,
providing financial stability that allows us to continuously invest in our
facilities."

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and
final product CMO with clinical and commercial production experience in
mammalian and microbial systems. This experience has been acquired by
developing new production processes for a number of international clients and
producing a wide variety of vaccines, recombinant proteins and live bacterial
products in our state-of-the-art, GMP-licensed facilities since inception in
2000.

Focused solely on biopharmaceuticals, SynCo acts as a
strategic, long-term partner delivering product on time to the highest
quality standards. SynCo's team is committed to exceeding customer
expectations, taking a truly collaborative approach to contract
manufacturing.

For more information, please visit www.syncobiopartners.com

For more information, please contact: SynCo Bio Partners B.V., Joanne McCudden PhD, +31-6-5534-8074, J.mccudden at syncobiopartners.com